OncoMatch/Clinical Trials/NCT07292038
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors
Is NCT07292038 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NM6603 for cancers.
Treatment: NM6603 — This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Advanced solid tumors (primarily advanced colorectal cancer or triple-negative breast cancer) confirmed by histology or cytology
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
Prior adequate standard therapy with documented progression or intolerance, or lack of available standard therapy options, or contraindications to standard therapy
Cannot have received: drug targeting the same mechanism of action or molecular target
Prior treatment with a drug targeting the same mechanism of action or molecular target
Cannot have received: chemotherapy
Chemotherapy, biologic therapy, macromolecular targeted therapy, or radiotherapy within 4 weeks before first dose
Cannot have received: biologic therapy
Chemotherapy, biologic therapy, macromolecular targeted therapy, or radiotherapy within 4 weeks before first dose
Cannot have received: macromolecular targeted therapy
Chemotherapy, biologic therapy, macromolecular targeted therapy, or radiotherapy within 4 weeks before first dose
Cannot have received: radiotherapy
Chemotherapy, biologic therapy, macromolecular targeted therapy, or radiotherapy within 4 weeks before first dose
Cannot have received: oral fluoropyrimidines
Oral fluoropyrimidines or other small molecule targeted agents received within 2 weeks or 5 half-lives before first dose (whichever is longer)
Cannot have received: small molecule targeted agents
Oral fluoropyrimidines or other small molecule targeted agents received within 2 weeks or 5 half-lives before first dose (whichever is longer)
Cannot have received: traditional Chinese medicine or herbal products with antitumor activity
Use of traditional Chinese medicine or herbal products with antitumor activity within 2 weeks before first dose
Lab requirements
Blood counts
Absolute neutrophil count 1500 per mm3 or greater; Platelet count 100000 per mm3 or greater with no transfusion or growth factor use within 14 days before first dose; Hemoglobin 9.0 g/dL or greater with no transfusion or stimulating factors within 14 days before first dose
Kidney function
Creatinine clearance 60 mL/min or greater (Cockcroft-Gault formula)
Liver function
Total bilirubin 1.5x ULN or less (patients with Gilbert syndrome allowed); AST and ALT 2.5x ULN or less without liver metastasis, or 5x ULN or less with liver metastasis
Cardiac function
INR 1.5x ULN or less and APTT 1.5x ULN or less; Left ventricular ejection fraction less than 50 percent, QTcF greater than 450 ms
Adequate organ and bone marrow function as defined below: Absolute neutrophil count 1500 per mm3 or greater; Platelet count 100000 per mm3 or greater with no transfusion or growth factor use within 14 days before first dose; Hemoglobin 9.0 g/dL or greater with no transfusion or stimulating factors within 14 days before first dose; Total bilirubin 1.5 times upper limit of normal (ULN) or less (patients with Gilbert syndrome allowed); AST and ALT 2.5 times ULN or less without liver metastasis, or 5 times ULN or less with liver metastasis; Creatinine clearance 60 mL/min or greater (Cockcroft-Gault formula); INR 1.5 times ULN or less and APTT 1.5 times ULN or less
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify